1
|
Stanzani F, de Moraes Paisani D, de
Oliveira A, de Souza RC, Perfeito JAJ and Faresin SM: Morbidity,
mortality, and categorization of the risk of perioperative
complications in lung cancer patients. J Bras Pneumol. 40:21–19.
2014. View Article : Google Scholar : PubMed/NCBI
|
2
|
Wong YH, Chen RH and Chen BS: Core and
specific network markers of carcinogenesis from multiple cancer
samples. J Theor Biol. 362:17–34. 2014. View Article : Google Scholar : PubMed/NCBI
|
3
|
Reno TA, Kim JY and Raz DJ: Triptolide
inhibits lung cancer cell migration, invasion, and metastasis. Ann
Thorac Surg. 100:1917–1824. 2015. View Article : Google Scholar : PubMed/NCBI
|
4
|
Justilien V and Fields AP: Utility and
applications of orthotopic models of human non-small cell lung
cancer (NSCLC) for the evaluation of novel and emerging cancer
therapeutics. Curr Protoc Pharmacol. 62:14.27.1–14.27.17. 2013.
|
5
|
Feldstein C and Romero C: Role of
endothelins in hypertension. Am J Ther. 14:147–153. 2007.
View Article : Google Scholar : PubMed/NCBI
|
6
|
Hynynen MM and Khalil RA: The vascular
endothelin system in hypertension-recent patents and discoveries.
Recent Pat Cardiov Drug Discov. 1:952006. View Article : Google Scholar
|
7
|
Yanagisawa M, Kurihara H, Kimura S, Tomobe
Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K and Masaki T: A novel
potent vasoconstrictor peptide produced by vascular endothelial
cells. Nature. 332:411–415. 1988. View
Article : Google Scholar : PubMed/NCBI
|
8
|
Dworkin S, Simkin J, Darido C, Partridge
DD, Georgy SR, Caddy J, Wilanowski T, Lieschke GJ, Doggett K, Heath
JK and Jane SM: Grainyhead-like 3 regulation of endothelin-1 in the
pharyngeal endoderm is critical for growth and development of the
craniofacial skeleton. Mech Dev. 133:77–90. 2014. View Article : Google Scholar : PubMed/NCBI
|
9
|
Grimshaw MJ: Endothelins and
hypoxia-inducible factor in cancer. Endocr Relat Cancer.
14:233–244. 2007. View Article : Google Scholar : PubMed/NCBI
|
10
|
Schrey MP, Patel KV and Tezapsidis N:
Bombesin and glucocorticoids stimulate human breast cancer cells to
produce endothelin, a paracrine mitogen for breast stromal cells.
Cancer Res. 52:1786–1790. 1992.PubMed/NCBI
|
11
|
Knowles J, Loizidou M and Taylor I:
Endothelin-1 and angiogenesis in cancer. Curr Vasc Pharmacol.
3:309–314. 2005. View Article : Google Scholar : PubMed/NCBI
|
12
|
Zhang WM, Zhou J and Ye QJ: Endothelin-1
enhances proliferation of lung cancer cells by increasing
intracellular free Ca2+. Life Sci. 82:764–771. 2008.
View Article : Google Scholar : PubMed/NCBI
|
13
|
Xu X, Mao W, Chen Q, Zhuang Q, Wang L, Dai
J, Wang H and Huang Z: Endostar, a modified recombinant human
endostatin, suppresses angiogenesis through inhibition of
Wnt/β-catenin signaling pathway. Plos One. 9:e1074632014.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Tamura K: Development of cell-cycle
checkpoint therapy for solid tumors. Jpn J Clin Oncol.
45:1097–1192. 2015.PubMed/NCBI
|
15
|
Gutschner T, Hämmerle M, Eissmann M, Hsu
J, Kim Y, Hung G, Revenko A, Arun G, Stentrup M, Gross M, et al:
The noncoding RNA MALAT1 is a critical regulator of the metastasis
phenotype of lung cancer cells. Cancer Res. 73:1180–1189. 2013.
View Article : Google Scholar : PubMed/NCBI
|
16
|
Rosanò L, Spinella F and Bagnato A:
Endothelin 1 in cancer: Biological implications and therapeutic
opportunities. Nat Rev Cancer. 13:637–651. 2013. View Article : Google Scholar : PubMed/NCBI
|
17
|
Fagan KA, McMurtry IF and Rodman DM: Role
of endothelin-1 in lung disease. Respir Res. 2:90–101. 2001.
View Article : Google Scholar : PubMed/NCBI
|
18
|
Fu L, Chen W, Guo W, Wang J, Tian Y, Shi
D, Zhang X, Qiu H, Xiao X, Kang T, et al: Berberine targets
AP-2/hTERT, NF-κB/COX-2, HIF-1α/VEGF and cytochrome-c/caspase
signaling to suppress human cancer cell growth. PLoS One.
8:e692402013. View Article : Google Scholar : PubMed/NCBI
|
19
|
Lau MT, Klausen C and Leung PCK:
E-cadherin inhibits tumor cell growth by suppressing PI3K/Akt
signaling via β-catenin-Egr1-mediated PTEN expression. Oncogene.
30:2753–2766. 2011. View Article : Google Scholar : PubMed/NCBI
|
20
|
Ridley AJ: RhoA, RhoB and RhoC have
different roles in cancer cell migration. J Microsc. 251:242–249.
2013. View Article : Google Scholar : PubMed/NCBI
|
21
|
Patterson DM, Gao D, Trahan DN, Johnson
BA, Ludwig A, Barbieri E, Chen Z, Diaz-Miron J, Vassilev L, Shohet
JM and Kim ES: Effect of MDM2 and vascular endothelial growth
factor inhibition on tumor angiogenesis and metastasis in
neuroblastoma. Angiogenesis. 14:255–266. 2011. View Article : Google Scholar : PubMed/NCBI
|
22
|
Spinella F, Rosanò L, Di Castro V,
Decandia S, Nicotra MR, Natali PG and Bagnato A: Endothelin-1 and
endothelin-3 promote invasive behavior via hypoxia-inducible
factor-1alpha in human melanoma cells. Cancer Res. 67:1725–1734.
2007. View Article : Google Scholar : PubMed/NCBI
|
23
|
Matsuura A, Yamochi W, Ki Kawashima,
Hirata S and Yokoyama M: Stimulatory interaction between vascular
endothelial growth factor and endothelin-1 on each gene expression.
Hypertension. 32:89–95. 1998. View Article : Google Scholar : PubMed/NCBI
|
24
|
Salani D, Di Castro V, Nicotra MR, Rosanò
L, Tecce R, Venuti A, Natali PG and Bagnato A: Role of endothelin-1
in neovascularization of ovarian carcinoma. Am J Pathol.
157:1537–1547. 2000. View Article : Google Scholar : PubMed/NCBI
|
25
|
Rosanò L, Spinella F, Di Castro V, Nicotra
MR, Dedhar S, de Herreros AG, Natali PG and Bagnato A: Endothelin-1
promotes epithelial-to-mesenchymal transition in human ovarian
cancer cells. Cancer Res. 65:11649–11657. 2005. View Article : Google Scholar : PubMed/NCBI
|
26
|
Xu G, Zhang W, Bertram P, Zheng XF and
McLeod H: Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR
pathway in common human tumors. Int J Oncol. 24:893–900.
2004.PubMed/NCBI
|
27
|
Beckner ME, Gobbel GT, Abounader R,
Burovic F, Agostino NR, Laterra J and Pollack IF: Glycolytic glioma
cells with active glycogen synthase are sensitive to PTEN and
inhibitors of PI3K and gluconeogenesis. Lab Invest. 85:1457–1470.
2005.PubMed/NCBI
|
28
|
Thomas WD, Zhang XD, Franco AV, Nguyen T
and Hersey P: TNF-related apoptosis-inducing ligand-induced
apoptosis of melanoma is associated with changes in mitochondrial
membrane potential and perinuclear clustering of mitochondria. J
Immunol. 165:5612–5620. 2000. View Article : Google Scholar : PubMed/NCBI
|
29
|
Ruth MC, Xu Y, Maxwell IH, Ahn NG, Norris
DA and Shellman YG: RhoC promotes human melanoma invasion in a
PI3K/Akt-dependent pathway. J Invest Dermatol. 126:862–868. 2006.
View Article : Google Scholar : PubMed/NCBI
|
30
|
Blanco-Aparicio C, Pequeño B, Moneo V,
Romero L, Leal JF, Velasco J, Fominaya J and Carnero A: Inhibition
of phosphatidylinositol-3-kinase synergizes with gemcitabine in
low-passage tumor cell lines correlating with Bax translocation to
the mitochondria. Anti-Cancer Drug. 16:977–987. 2005. View Article : Google Scholar
|
31
|
Del Bufalo D, Di Castro V, Biroccio A,
Varmi M, Salani D, Rosanò L, Trisciuoglio D, Spinella F and Bagnato
A: Endothelin-1 protects ovarian carcinoma cells against
paclitaxel-induced apoptosis: Requirement for Akt activation. Mol
Pharmacol. 61:524–532. 2002. View Article : Google Scholar : PubMed/NCBI
|
32
|
Leahy KM, Ornberg RL, Wang Y, Zweifel BS,
Koki AT and Masferrer JL: Cyclooxygenase-2 inhibition by celecoxib
reduces proliferation and induces apoptosis in angiogenic
endothelial cells in vivo. Cancer Res. 62:625–631. 2002.PubMed/NCBI
|
33
|
Hsieh HL, Sun CC, Wang TS and Yang CM:
PKC-delta/c-Src-mediated EGF receptor transactivation regulates
thrombin-induced COX-2 expression and PGE(2) production in rat
vascular smooth muscle cells. Biochim Biophys Acta. 1783:1563–1575.
2008. View Article : Google Scholar : PubMed/NCBI
|
34
|
Appleby SB, Ristimäki A, Neilson K, Narko
K and Hla T: Structure of the human cyclo-oxygenase-2 gene. Biochem
J. 302:723–727. 1994. View Article : Google Scholar : PubMed/NCBI
|
35
|
Morita I, Schindler M, Regier MK, Otto JC,
Hori T, DeWitt DL and Smith WL: Different intracellular locations
for prostaglandin endoperoxide H synthase-1 and −2. J Biol Chem.
270:10902–10908. 1995. View Article : Google Scholar : PubMed/NCBI
|
36
|
Murata H, Kawano S, Tsuji S, Tsuji M,
Sawaoka H, Kimura Y, Shiozaki H and Hori M: Cyclooxygenase-2
overexpression enhances lymphatic invasion and metastasis in human
gastric carcinoma. Am J Gastroenterol. 94:451–455. 1999. View Article : Google Scholar : PubMed/NCBI
|
37
|
Narumiya S, Tanji M and Ishizaki T: Rho
signaling, ROCK and mDia1, in transformation, metastasis and
invasion. Cancer Metastasis Rev. 28:65–76. 2009. View Article : Google Scholar : PubMed/NCBI
|
38
|
Wong CM and Ng IO: Molecular pathogenesis
of hepatocellular carcinoma. Liver Int. 28:160–174. 2008.
View Article : Google Scholar : PubMed/NCBI
|
39
|
Wang M, Wang XJ and Liu BR: Effect of
shRNA targeted against RhoA on proliferation and migration of human
colonic cancer cells. Int J Clin Exp Pathol. 8:7040–7044.
2015.PubMed/NCBI
|
40
|
He X, Qian Y, Cai H and Wang Z: The effect
of RhoC siRNA on the invasiveness and proliferation of human
cervical cancer cell line SiHa cells. J Huazhong Univ Sci Technolog
Med Sci. 28:665–669. 2008. View Article : Google Scholar : PubMed/NCBI
|
41
|
Hakem A, Sanchez-Sweatman O, You-Ten A,
Duncan G, Wakeham A, Khokha R and Mak TW: RhoC is dispensable for
embryogenesis and tumor initiation but essential for metastasis.
Genes Dev. 19:1974–1999. 2005. View Article : Google Scholar : PubMed/NCBI
|
42
|
Li NF, Gemenetzidis E, Marshall FJ, Davies
D, Yu Y, Frese K, Froeling FE, Woolf AK, Feakins RM, Naito Y, et
al: RhoC interacts with integrin α5β1 and enhances its trafficking
in migrating pancreatic carcinoma cells. PLoS One. 8:0e815752013.
View Article : Google Scholar
|
43
|
Kleer CG, van Golen KL, Zhang Y, Wu ZF,
Rubin MA and Merajver SD: Characterization of RhoC expression in
benign and malignant breast disease: a potential new marker for
small breast carcinomas with metastatic ability. Am J Pathol.
160:579–584. 2002. View Article : Google Scholar : PubMed/NCBI
|
44
|
Pillé JY, Denoyelle C, Varet J, Bertrand
JR, Soria J, Opolon P, Lu H, Pritchard LL, Vannier JP, Malvy C, et
al: Anti-RhoA and anti-RhoC siRNAs inhibit the proliferation and
invasiveness of MDA-MB-231 breast cancer cells in vitro and in
vivo. Mol Ther. 11:267–274. 2005. View Article : Google Scholar : PubMed/NCBI
|
45
|
Yu YF, Zhang Y, Shen N, Zhang RY and Lu
XQ: Effect of VEGF, P53 and telomerase on angiogenesis of gastric
carcinoma tissue. Asian Pac J Trop Med. 7:293–296. 2014. View Article : Google Scholar : PubMed/NCBI
|
46
|
van Golen KL, Wu ZF, Qiao XT, Bao L and
Merajver SD: RhoC GTPase overexpression modulates induction of
angiogenic factors in breast cells. Neoplasia. 2:418–425. 2000.
View Article : Google Scholar : PubMed/NCBI
|
47
|
Fukata M and Kaibuchi K: Rho-family
GTPases in cadherin-mediated cell-cell adhesion. Nat Rev Mol Cell
Bio. 2:887–897. 2001. View Article : Google Scholar
|
48
|
Kidera Y, Tsubaki M, Yamazoe Y, Shoji K,
Nakamura H, Ogaki M, Satou T, Itoh T, Isozaki M, Kaneko J, et al:
Reduction of lung metastasis, cell invasion, and adhesion in mouse
melanoma by statin-induced blockade of the Rho/Rho-associated
coiled-coil-containing protein kinase pathway. J Exp Clin Cancer
Res. 29:1272010. View Article : Google Scholar : PubMed/NCBI
|
49
|
Bernard A, Gao-Li J, Franco CA, Bouceba T,
Huet A and Li Z: Laminin receptor involvement in the
anti-angiogenic activity of pigment epithelium-derived factor. J
Biol Chem. 284:10480–10490. 2009. View Article : Google Scholar : PubMed/NCBI
|
50
|
Mahtabifard A, Merritt RE, Yamada RE,
Crystal RG and Korst RJ: In vivo gene transfer of pigment
epithelium-derived factor inhibits tumor growth in syngeneic murine
models of thoracic malignancies. J Thorac Cardiov Surg. 126:28–38.
2003. View Article : Google Scholar : PubMed/NCBI
|
51
|
Takenaka K, Yamagishi S, Jinnouchi Y,
Nakamura K, Matsui T and Imaizumi T: Pigment epithelium-derived
factor (PEDF)-induced apoptosis and inhibition of vascular
endothelial growth factor (VEGF) expression in MG63 human
osteosarcoma cells. Life Sci. 77:3231–3241. 2005. View Article : Google Scholar : PubMed/NCBI
|
52
|
Zhang L, Chen J, Ke Y, Mansel RE and Jiang
WG: Expression of pigment epithelial derived factor is reduced in
non-small cell lung cancer and is linked to clinical outcome. Int J
Mol Med. 17:937–944. 2006.PubMed/NCBI
|
53
|
Huang X, Chen L, Fu G, Xu H and Zhang X:
Decreased expression of pigment epithelium-derived factor and
increased microvascular density in ovarian endometriotic lesions in
women with endometriosis. Eur J Obstet Gynecol Reprod Biol.
165:104–109. 2012. View Article : Google Scholar : PubMed/NCBI
|
54
|
Chen J, Ye L, Zhang L and Jiang WG: The
molecular impact of pigment epithelium-derived factor, PEDF, on
lung cancer cells and the clinical significance. Int J Oncol.
35:159–166. 2009.PubMed/NCBI
|
55
|
Abe R, Fujita Y and Yamagishi S:
Angiogenesis and metastasis inhibitors for the treatment of
malignant melanoma. Mini Rev Med Chem. 7:649–661. 2007. View Article : Google Scholar : PubMed/NCBI
|